Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN Stock Report

Market Cap: US$76.7b

Regeneron Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 5/6

Regeneron Pharmaceuticals has a total shareholder equity of $29.4B and total debt of $2.0B, which brings its debt-to-equity ratio to 6.8%. Its total assets and total liabilities are $37.8B and $8.4B respectively. Regeneron Pharmaceuticals's EBIT is $4.1B making its interest coverage ratio -6.2. It has cash and short-term investments of $9.0B.

Key information

6.8%

Debt to equity ratio

US$1.98b

Debt

Interest coverage ratio-6.2x
CashUS$9.01b
EquityUS$29.35b
Total liabilitiesUS$8.41b
Total assetsUS$37.76b

Recent financial health updates

Recent updates

Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025

Feb 04

Regeneron: Phase III Success In Skin Cancer For Libtayo

Jan 15

Regeneron's Diversified Growth Makes It My Top Biopharma Pick For 2025

Jan 05

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Dec 13
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Regeneron: Recent Bear Run May Be Justified -- Pharma Faces A Testing 2025

Dec 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings

Nov 22
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings

Regeneron: The Biotech Stock To Buy Now

Nov 19

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Nov 04

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Sep 25

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Sep 09
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Regeneron Stock: Valuation Now Demands More Growth

Aug 26

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 22
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04
Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Financial Position Analysis

Short Term Liabilities: REGN's short term assets ($18.7B) exceed its short term liabilities ($3.9B).

Long Term Liabilities: REGN's short term assets ($18.7B) exceed its long term liabilities ($4.5B).


Debt to Equity History and Analysis

Debt Level: REGN has more cash than its total debt.

Reducing Debt: REGN's debt to equity ratio has increased from 0% to 6.8% over the past 5 years.

Debt Coverage: REGN's debt is well covered by operating cash flow (222.8%).

Interest Coverage: REGN earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 23:10
End of Day Share Price 2025/02/06 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Regeneron Pharmaceuticals, Inc. is covered by 60 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Brian SkorneyBaird
Ishan MajumdarBaptista Research